Stocks are down midday Monday, with the Dow Jones Industrial Average down 0.30%, the Nasdaq down 0.22% and the S&P 500 down 0.15%. Today’s big winners are two pharmaceutical companies, with one getting bought out by private equity and another showing a successful trial of one of its drugs. Meanwhile, a stock sale sends a medical technology company lower while energy woes continue to hit the coal sector, sending one company on the loser list.
Here are Monday’s market winners and losers.
Biggest Winners
Shares of Par Pharmaceuticals (NYSE: PRX) are up 37.21% to $50.16 on trading volume of 3.9 million shares. Private equity firm TPG announced Monday it would purchase Par for $1.9 billion, or $50 a share. Before Monday, the 52-week high was $42.80.
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are up 26.12% to $15.79 on trading volume of 1.9 million shares. The company announced positive results from its Phase I trial of ALN-TTR02 , which helps treat a form of amylodosis. Before Monday, the 52-week high was $13.75.
Biggest Losers
Shares of IsoRay (ASE: ISR) are down 21.09% to $1.16 on trading volume of 2.7 million shares. The medical technology company announced it is selling about $3.5 million of its common stock. The 52-week low of the stock is $0.38.
Shares of Alpha Natural Resources (NYSE: ANR) are down 10.68% to $6.82 on trading volume of 7.1 million shares. Energy stocks are taking a big hit Monday, and Alpha Natural was cut to “underperform” by BMO Capital Markets, according to MarketWatch. Before Monday, the 52-week low was $7.17.
Samuel Weigley
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.